Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Opyl Ltd. ( (AU:PKY) ).
Pathkey’s March quarter update shows continued investment in developing TrialKey as a scalable, AI-driven tool for clinical trial design, adding a Criteria Optimiser that uses agentic AI workflows to generate and rank protocol options under safety and feasibility constraints. The company is also building a customer-facing SaaS platform to support recurring revenue by letting clients run their own models for trial design, protocol refinement and competitive benchmarking.
During and after the quarter, Pathkey signed its largest commercial contract to date with Imunexus Therapeutics, worth up to A$100,000 plus GST, validating TrialKey’s use in probability-of-success analysis, early-phase trial optimisation and IPO preparation. The company also secured an option to acquire 100% of Chipforge, whose AI platform converts high-level chip design intent into verified hardware code, positioning Pathkey to apply its agent-based optimisation paradigm across both clinical development and semiconductor design while supported by a strengthened balance sheet and A$3.26 million in cash.
More about Opyl Ltd.
Pathkey.AI Ltd, listed on the ASX as PKY, operates in the AI-driven life sciences and technology sector, specialising in clinical trial optimisation through its TrialKey decision-support platform. The company is now extending its agentic AI expertise into semiconductor hardware design via the proposed acquisition of Singapore-based Chipforge, an AI-enabled chip design and verification business.
Average Trading Volume: 2,932,746
Technical Sentiment Signal: Hold
Current Market Cap: A$31.57M
For a thorough assessment of PKY stock, go to TipRanks’ Stock Analysis page.